Tuesday, November 17, 2015 6:30:46 PM
2014
December – Dosed first cancer patient with entolimod in Russian Federation
October – Opened IND for entolimod in the Russian Federation
October – Dosed first healthy subject with CBLB612 in Russian Federation
September – Achieved agreement with FDA that existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod’s biodefense indication
September – Completed enrollment of Phase 1 advanced cancer trial with entolimod at Roswell Park Cancer Institute
August – Opened IND for CBLB612 in the Russian Federation
April – Reported Phase 1 trial for CBL0102 (predecessor to CBL0137)
http://www.cbiolabs.com/history
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM